FR2847253B1 - Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant - Google Patents

Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant

Info

Publication number
FR2847253B1
FR2847253B1 FR0214443A FR0214443A FR2847253B1 FR 2847253 B1 FR2847253 B1 FR 2847253B1 FR 0214443 A FR0214443 A FR 0214443A FR 0214443 A FR0214443 A FR 0214443A FR 2847253 B1 FR2847253 B1 FR 2847253B1
Authority
FR
France
Prior art keywords
pyridazinones
medicaments
pharmaceutical compositions
novel derivatives
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0214443A
Other languages
English (en)
French (fr)
Other versions
FR2847253A1 (fr
Inventor
Dominique Lesuisse
Franck Halley
Bernard Baudoin
Thomas Rooney
Swen Hoelder
Thorsten Naumann
Gilles Tiraboschi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0214443A priority Critical patent/FR2847253B1/fr
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Priority to US10/715,358 priority patent/US7309701B2/en
Priority to PCT/EP2003/012949 priority patent/WO2004046130A1/en
Priority to JP2004552660A priority patent/JP2006509748A/ja
Priority to EP03775372A priority patent/EP1581505B1/en
Priority to BR0316720-8A priority patent/BR0316720A/pt
Priority to AT03811383T priority patent/ATE369356T1/de
Priority to ARP030104278A priority patent/AR042202A1/es
Priority to PCT/EP2003/012950 priority patent/WO2004046117A1/en
Priority to EP03811383A priority patent/EP1611121B1/en
Priority to AU2003296586A priority patent/AU2003296586A1/en
Priority to US10/715,556 priority patent/US7462613B2/en
Priority to CA002518917A priority patent/CA2518917A1/en
Priority to KR1020057009083A priority patent/KR20050083918A/ko
Priority to AT03775372T priority patent/ATE368651T1/de
Priority to TW092132459A priority patent/TW200503727A/zh
Priority to AU2003283414A priority patent/AU2003283414A1/en
Priority to TW092132354A priority patent/TW200418478A/zh
Priority to DE60315354T priority patent/DE60315354T2/de
Priority to ARP030104280A priority patent/AR042089A1/es
Priority to CA002506022A priority patent/CA2506022A1/en
Priority to MXPA05005270A priority patent/MXPA05005270A/es
Priority to PL03376129A priority patent/PL376129A1/xx
Priority to RU2005119151/04A priority patent/RU2005119151A/ru
Priority to CNA2003801050578A priority patent/CN1741999A/zh
Priority to DE60315516T priority patent/DE60315516T2/de
Publication of FR2847253A1 publication Critical patent/FR2847253A1/fr
Priority to MA28287A priority patent/MA27814A1/fr
Priority to CO05048069A priority patent/CO5700722A2/es
Priority to NO20052887A priority patent/NO20052887L/no
Application granted granted Critical
Publication of FR2847253B1 publication Critical patent/FR2847253B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FR0214443A 2002-11-19 2002-11-19 Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant Expired - Fee Related FR2847253B1 (fr)

Priority Applications (29)

Application Number Priority Date Filing Date Title
FR0214443A FR2847253B1 (fr) 2002-11-19 2002-11-19 Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
TW092132354A TW200418478A (en) 2002-11-19 2003-11-19 Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
JP2004552660A JP2006509748A (ja) 2002-11-19 2003-11-19 Ｇｓｋ−３ベータ阻害剤としてのピリダジノン誘導体
EP03775372A EP1581505B1 (en) 2002-11-19 2003-11-19 Pyridazinone derivatives as gsk-3beta inhibitors
BR0316720-8A BR0316720A (pt) 2002-11-19 2003-11-19 Derivados de piridazinona como inibidores de gsk-3beta
AT03811383T ATE369356T1 (de) 2002-11-19 2003-11-19 Pyridazinon-derivate als cdk2-hemmer
ARP030104278A AR042202A1 (es) 2002-11-19 2003-11-19 Derivados de piridazinona como medicamentos y composiciones farmaceuticas que los contienen
PCT/EP2003/012950 WO2004046117A1 (en) 2002-11-19 2003-11-19 Pyridazinone derivatives as gsk-3beta inhibitors
EP03811383A EP1611121B1 (en) 2002-11-19 2003-11-19 Pyridazinone derivatives as cdk2-inhibitors
AU2003296586A AU2003296586A1 (en) 2002-11-19 2003-11-19 Pyridazinone derivatives as cdk2-inhibitors
US10/715,556 US7462613B2 (en) 2002-11-19 2003-11-19 Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
CA002518917A CA2518917A1 (en) 2002-11-19 2003-11-19 Pyridazinone derivatives as cdk2-inhibitors
KR1020057009083A KR20050083918A (ko) 2002-11-19 2003-11-19 Ｇｓｋ-3베타 억제제로서의 피리다지논 유도체
AT03775372T ATE368651T1 (de) 2002-11-19 2003-11-19 Pyridazinon-derivate als gsk-3beta-hemmer
US10/715,358 US7309701B2 (en) 2002-11-19 2003-11-19 Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
AU2003283414A AU2003283414A1 (en) 2002-11-19 2003-11-19 Pyridazinone derivatives as gsk-3beta inhibitors
ARP030104280A AR042089A1 (es) 2002-11-19 2003-11-19 Derivados de piridazinona como medicamentos, metodos para su preparacion y composiciones farmaceuticas que los contienen
PCT/EP2003/012949 WO2004046130A1 (en) 2002-11-19 2003-11-19 Pyridazinone derivatives as cdk2-inhibitors
DE60315354T DE60315354T2 (de) 2002-11-19 2003-11-19 Pyridazinon-derivate als gsk-3beta-hemmer
CA002506022A CA2506022A1 (en) 2002-11-19 2003-11-19 Pyridazinone derivatives as gsk-3beta inhibitors
MXPA05005270A MXPA05005270A (es) 2002-11-19 2003-11-19 Nuevos derivados de piridazinona como productos farmaceuticos y composiciones farmaceuticas que los contienen.
PL03376129A PL376129A1 (en) 2002-11-19 2003-11-19 Pyridazinone derivatives as gsk-3beta inhibitors
RU2005119151/04A RU2005119151A (ru) 2002-11-19 2003-11-19 Производные пиридазинона в качестве gsk-3бета-ингибиторов
CNA2003801050578A CN1741999A (zh) 2002-11-19 2003-11-19 用作GSK－3β抑制剂的哒嗪酮衍生物
DE60315516T DE60315516T2 (de) 2002-11-19 2003-11-19 Pyridazinon-derivate als cdk2-hemmer
TW092132459A TW200503727A (en) 2002-11-19 2003-11-19 Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
MA28287A MA27814A1 (fr) 2002-11-19 2005-05-17 Derives de pyridazinones en tant qu'inhibiteurs de gsk-3beta
CO05048069A CO5700722A2 (es) 2002-11-19 2005-05-18 Nuevos derivados de piridazinona como productos farmaceutico y composiciones farmaceuticas que los contienen
NO20052887A NO20052887L (no) 2002-11-19 2005-06-14 Pyridazinonderivater som GSK-3Beta inhibitorer.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0214443A FR2847253B1 (fr) 2002-11-19 2002-11-19 Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant

Publications (2)

Publication Number Publication Date
FR2847253A1 FR2847253A1 (fr) 2004-05-21
FR2847253B1 true FR2847253B1 (fr) 2007-05-18

Family

ID=32187711

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0214443A Expired - Fee Related FR2847253B1 (fr) 2002-11-19 2002-11-19 Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant

Country Status (19)

Country Link
EP (2) EP1581505B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006509748A (cg-RX-API-DMAC7.html)
KR (1) KR20050083918A (cg-RX-API-DMAC7.html)
CN (1) CN1741999A (cg-RX-API-DMAC7.html)
AR (2) AR042089A1 (cg-RX-API-DMAC7.html)
AT (2) ATE369356T1 (cg-RX-API-DMAC7.html)
AU (2) AU2003283414A1 (cg-RX-API-DMAC7.html)
BR (1) BR0316720A (cg-RX-API-DMAC7.html)
CA (2) CA2506022A1 (cg-RX-API-DMAC7.html)
CO (1) CO5700722A2 (cg-RX-API-DMAC7.html)
DE (2) DE60315516T2 (cg-RX-API-DMAC7.html)
FR (1) FR2847253B1 (cg-RX-API-DMAC7.html)
MA (1) MA27814A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05005270A (cg-RX-API-DMAC7.html)
NO (1) NO20052887L (cg-RX-API-DMAC7.html)
PL (1) PL376129A1 (cg-RX-API-DMAC7.html)
RU (1) RU2005119151A (cg-RX-API-DMAC7.html)
TW (2) TW200418478A (cg-RX-API-DMAC7.html)
WO (2) WO2004046117A1 (cg-RX-API-DMAC7.html)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2264014A1 (en) 2001-08-31 2010-12-22 Université Louis Pasteur Substituted pyridazines as anti-inflammatory agents and protein kinase inhibitors
DE102004010207A1 (de) 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
DE102004010194A1 (de) 2004-03-02 2005-10-13 Aventis Pharma Deutschland Gmbh 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln
EP1598348A1 (en) 2004-05-18 2005-11-23 Aventis Pharma Deutschland GmbH Novel pyridazinone derivatives as inhibitors of CDK2
EP1604988A1 (en) 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
EP1799664A1 (en) 2004-09-20 2007-06-27 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP1799667B1 (en) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
CA2580845A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
BRPI0515505A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados heterocìclicos e sua utilização como inibidores da estearoil-coa desaturase
WO2006101521A2 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AR051026A1 (es) 2004-09-20 2006-12-13 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
ATE523199T1 (de) 2004-11-02 2011-09-15 Univ Northwestern Pyridazinverbindungen und verfahren
CN101087766B (zh) 2004-11-02 2011-09-07 西北大学 哒嗪化合物、组合物和方法
CA2618646A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007127475A2 (en) * 2006-04-28 2007-11-08 Northwestern University Pyridazines for demyelinating diseases and neuropathic pain
EP2015750A2 (en) * 2006-04-28 2009-01-21 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
US20090325973A1 (en) 2006-04-28 2009-12-31 Watterson D Martin Formulations containing pyridazine compounds
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2009001043A (es) 2006-08-08 2009-02-06 Sanofi Aventis Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para preparalas, medicamentos que comprenden estos compuestos y su uso.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101538245B (zh) 2008-03-18 2011-02-16 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和制备药物的用途
US9212146B2 (en) 2008-03-18 2015-12-15 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Substituted pyridazinones for the treatment of tumors
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
AU2012203023C1 (en) * 2009-03-02 2013-11-07 Novartis Ag N-(hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as Wnt signaling modulators
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
US8785608B2 (en) 2009-08-26 2014-07-22 Sanofi Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
GB201201100D0 (en) * 2012-01-20 2012-03-07 Medical Res Council Polypeptides and methods
HUE060767T2 (hu) 2013-10-18 2023-04-28 Celgene Quanticel Res Inc Brómdomén inhibitorok
WO2015127137A1 (en) * 2014-02-19 2015-08-27 Aldea Pharmaceuticals, Inc. Mitochondrial aldehyde dehydrogenase 2 (aldh2) binding polycyclic amides and their use for the treatment of cancer
AU2017269870A1 (en) * 2016-05-25 2018-12-06 Bayer Pharma Aktiengesellschaft 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
JOP20190193A1 (ar) * 2017-02-09 2019-08-08 Bayer Pharma AG ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
CA3082856A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
CN111533697B (zh) * 2020-05-07 2023-03-31 成都大学 4-氨基哒嗪酮类化合物及其制备方法
CN111533735A (zh) * 2020-05-08 2020-08-14 张建蒙 氧代二氢哒嗪噻唑类衍生物及其在抗肿瘤药物中的应用
CN111393374A (zh) * 2020-05-08 2020-07-10 张建蒙 氧代二氢哒嗪类衍生物及其在抗肿瘤药物中的应用
AR124154A1 (es) 2020-11-27 2023-02-22 Rhizen Pharmaceuticals Ag Inhibidores de cdk
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
IL308314A (en) 2021-05-07 2024-01-01 Kymera Therapeutics Inc CDK2 compounds and their uses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134467A1 (de) * 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4127404A1 (de) * 1991-08-19 1993-02-25 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPH09216883A (ja) * 1996-02-09 1997-08-19 Fujisawa Pharmaceut Co Ltd ピラゾロピリジン化合物および該化合物を含有する医薬
AU2010399A (en) * 1997-12-24 1999-07-19 Affymetrix, Inc. Methods of using chemical libraries to search for new kinase inhibitors
TWI241295B (en) * 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
US6440959B1 (en) * 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
WO2002022587A1 (en) * 2000-09-18 2002-03-21 Eisai Co., Ltd. Pyridazinones and triazinones and medicinal use thereof
EP1345926B1 (en) * 2000-12-21 2006-05-17 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors

Also Published As

Publication number Publication date
EP1581505A1 (en) 2005-10-05
CO5700722A2 (es) 2006-11-30
RU2005119151A (ru) 2006-01-20
CA2506022A1 (en) 2004-06-03
ATE368651T1 (de) 2007-08-15
PL376129A1 (en) 2005-12-12
BR0316720A (pt) 2005-10-18
JP2006509748A (ja) 2006-03-23
WO2004046117A1 (en) 2004-06-03
NO20052887D0 (no) 2005-06-14
MA27814A1 (fr) 2006-04-03
DE60315354D1 (de) 2007-09-13
AU2003296586A1 (en) 2004-06-15
DE60315516D1 (de) 2007-09-20
FR2847253A1 (fr) 2004-05-21
ATE369356T1 (de) 2007-08-15
EP1611121B1 (en) 2007-08-08
WO2004046130A1 (en) 2004-06-03
KR20050083918A (ko) 2005-08-26
AR042202A1 (es) 2005-06-15
TW200503727A (en) 2005-02-01
MXPA05005270A (es) 2005-07-25
TW200418478A (en) 2004-10-01
NO20052887L (no) 2005-07-29
DE60315354T2 (de) 2008-05-08
AU2003283414A1 (en) 2004-06-15
CN1741999A (zh) 2006-03-01
AR042089A1 (es) 2005-06-08
EP1611121A1 (en) 2006-01-04
DE60315516T2 (de) 2008-04-17
EP1581505B1 (en) 2007-08-01
CA2518917A1 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
FR2847253B1 (fr) Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
MA27392A1 (fr) Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
FR16C0042I2 (fr) Derives de composes heterocycliques et medicaments
HUE040046T2 (hu) Gyógyszerészeti készítmények és hatóanyagok beadására szolgáló eljárások
NO20021599L (no) Nye farmasöytiske sammensetninger av anti-tuberkulose legemidler og fremgangsmåte for deres fremstilling
NO20042842L (no) Farmasoytiske formuleringer av platina-derivat
EE200300207A (et) Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon
PT1221918E (pt) Administracao de drogas sub-tenon
FR2761066B1 (fr) Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
NO20035438L (no) Farmasoytisk formulering for effektiv administrering av apomorfin, 6aR-(-)-N-propyl-norapomorfin og deres derivater og prodrugs derav
CY2007033I1 (el) Μεθοδος και φαρμακευτικο σκευασμα για την αντιμετωπιση της αντιστασης στα αντιυπερτασικα φαρμακα και για σχετικες παθησεις
FR2807038B1 (fr) Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
MA26882A1 (fr) COMPOSITIONS PHARMACEUTIQUES D'INHIBITEURS ET GLYCOGèNE-PHOSPHORYLASE
FR2911138B1 (fr) Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2862647B1 (fr) Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
FR2873691B1 (fr) Derives d'amino-piperidine, leur preparation et leur application en therapeutique
FR2919869B1 (fr) Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2840302B1 (fr) Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
FR2850377B1 (fr) Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
FR2854159B1 (fr) Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
IL166098A0 (en) 3-guanindinocarbonyl-1-heteroaryl-indole derivatives preparation process their use as medicaments and pharmaceutical compositions comprising them
IL166097A0 (en) Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole preparation process and intermediates of this process their use as medicaments and pharmaceutical compositions comprising them
EP1507764A4 (en) NOVEL ENANTIOMERS OF TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS THEREOF
FR2873693B1 (fr) Derives d'amino-tropane, leur preparation et leur application en therapeutique
FR2842808B1 (fr) Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20160729